One of the big market stories of 2023 has been the sudden rise of GLP-1 weight loss and diabetes drugs. Healthcare is not normally a sector we associate with high volatility: that has changed this year. Hype around the potentially massive opportunity for GLP-1 drugs has seen the stock prices of their developers, Novo Nordisk and Eli Lilly, soar.
Access Forsyth Barr research
Explore our research reports, news and analysis by logging into your account.
If you are not yet a client, create an account to read reports and view market announcements and company news.